WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Extraordinary video captures moment epileptic woman's dogs spot her seizure and run to the rescueBeyonce's mom Tina Knowles eviscerates Charles Barkley and Shaq for calling Texas' beaches 'dirty'Drury, Noesen help Hurricanes beat Islanders 6Rojas and Castellanos homer in the 9th, leading the Phillies to a 7It wasn't me, Rylan Clark insists after police release eOpenAI lawsuit: Eight major U.S. newspapers sue ChatGPTJelly Roll's exWhat to stream this week: Dua Lipa, Seinfeld’s ‘Unfrosted’ and ‘Welcome to Wrexham’Harvey Weinstein to return to court Wednesday after his NY rape conviction was overturnedTOWIE's Tommy Mallet says he has 'sold everything' after being hit by a huge tax bill
2.6749s , 6605.4765625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Gaze news portal